Torrent Loses US Infringement Battle Over Supernus’ Trokendi XR

Trio Of Originator Patents Protecting Topiramate Brand Will Expire In 2027

While a US district court sided with Supernus over its patent infringement claims against Torrent, the court’s opinion was sealed due to confidential and proprietary information.

Torrent Pharma logo
Torrent infringed three patents, which were ruled to be valid • Source: Shutterstock

Supernus Pharmaceuticals is waving a victory flag after a US District Court in New Jersey ruled in its favor over Trokendi XR (topiramate extended-release) patent infringement claims against Torrent Pharmaceuticals.

A four-day bench trial was held last summer, with the court ordering on 11 December 2023 that “Torrent has voluntarily...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin